Journal
PHARMACEUTICALS
Volume 13, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/ph13090237
Keywords
GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy
Categories
Funding
- Shanghai Municipal Government
- ShanghaiTech University
Ask authors/readers for more resources
The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available